Genetic rearrangements of the ALK kinase occur in 3-13% of non-small cell lung cancer patients and rarely co-exist with KRAS or EGFR mutations. To evaluate potential treatment strategies for lung cancers driven by an activated EML4-ALK chimeric oncogene, we generated a genetically engineered mouse model that Research.
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Copyright © 2010 American Association for Cancer Research 8 JP1536HA was created by inserting a Flag-tag and an HA-tag before the lox-P site of JP1520 vector to allow tagging at the N-terminus of the shuttled construct. The EML4-ALK variant 1 was shuttled into JP1536HA, using the BD Creator System (BD Biosciences). The empty retroviral construct JP1536HA was used as control.
H3122 cells were infected with retrovirus according to standard protocols as described previously (13) .
Tandem Affinity Purification, Silver staining and LC-MS/MS. Lysates from
H3122-EML4-ALK-JP1536HA or H3122-JP1536HA-expressing cells were prepared in Flag IP buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% NP-40, 1 mM EDTA, 10% glycerol, supplemented with EDTA-free Roche protease inhibitor cocktail). Two mg of lysate was incubated with 20 μl of anti-FLAG agarose.
FLAG-tagged protein was purified by affinity purification and eluted with Flag peptide (Sigma). The eluate was incubated with 20 μl of anti-HA agarose with HA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% NP-40, 1 mM EDTA, 10%
glycerol, supplemented with EDTA-free Roche protease inhibitor cocktail).
HA-tagged proteins were eluted with HA peptide (Covance) from HA-agarose. 10%
of the final eluate was analyzed by silver staining (SilverQuest Silver Staining Kit, invitrogen Carlsbad, CA), according to the manufacturer's instructions. The remaining 90% of the purified protein complexes were analyzed by a gel-free
Expression of the EML4-ALK V1 fusion protein in mice leads to lung
adenocarcinoma that is similar to the human disease.
We generated doxycycline-inducible bitransgenic mice harboring the EML4-ALK (V1) allele ( (Fig. S1B) . ALK-rearranged lung cancers in humans are also predominately observed in adenocarcinomas (8) . Although signet ring cell features have been observed in human ALK-rearranged lung cancers, we did not observe signet ring cells in the murine cancers (8, 29) .
Research. .
ALK kinase inhibitor is a more effective therapy than chemotherapy in

EML4-ALK murine lung adenocarcinoma
The current standard of care for advanced lung cancer is cytotoxic chemotherapy.
However for subsets of lung cancer, defined by an activated kinase oncogenic driver, kinase inhibitors may be more effective, as recently demonstrated for gefitinib in EGFR mutant disease (30) . We therefore investigated whether a similar therapeutic paradigm would apply to EML4-ALK lung cancer in our preclinical model. We
Research. (Fig. 1A) . Continuous treatment did not result in further tumor regression. Instead, resistance rapidly developed, and the tumors progressed and exceeded the original tumor burden by 5 weeks of treatment (Fig. 1A) . In contrast, all of the TAE684-treated mice achieved complete regression within 2 weeks.
Histological analysis showed grossly normal lung structure without evidence of tumor cells (Fig. 1B) . Additionally, the clinical condition of tumor-bearing TAE684-treated mice improved rapidly (Fig. S1C) (Fig. 1D) . 
Inhibition
EML4-ALK interacts with HSP family members
In order to further study ALK signaling and to identify additional potential therapeutic targets, we examined EML4-ALK-associated proteins using Tandem Affinity Purification (TAP) coupled with mass spectrometry. We constructed an EML4-ALK V1 expression vector tagged with FLAG and HA, introduced it into H3122 cells followed by two rounds of immunoprecipitation-based purification (Fig.   3A ). We identified several interacting proteins ( Fig. 3A ) and analyzed these by MS (Table S3A ). As anticipated, we detected EML4 (both full length and EML4-ALK)
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on January S4C and S4D). Neither protein was detected in the control affinity purification.
To validate the physical association of the HSP protein complex and EML4-ALK, we performed co-immunoprecipitation experiments using the FLAG/HA tagged EML4-ALK expression construct. Both HSPA5 and HSPA8, which were identified by MS, co-precipitated with EML4-ALK (Fig 3B) . Moreover, additional HSP family members, including HSPA1A (HSP70) and HSP90, were also detected in association with EML4-ALK (Fig. 3B ). We further confirmed the endogenous association of HSP90 in the H3122 cells with ALK by immunoprecipitation with an HSP90 antibody.
ALK, as well as two other known HSP90 partners, cdc37 and p23, were detected in complex with HSP90 (Fig. 3B) . The association of EML4-ALK and HSP90 was disrupted by 17-AAG-mediated HSP90 inhibition (Fig. 3B ). These findings suggest that HSP family members may play a critical role in protein folding and structural stability of EML4-ALK.
To determine a functional role for HSP family members in maintaining stability of EML4-ALK, we treated H3122 cells with 17-AAG. EML4-ALK was efficiently
Research. (Fig. 3C ).
HSP70 expression was up-regulated with treatment, a pharmacodynamic marker of effective HSP90 inhibition (42) . Furthermore, 17-AAG inhibited H3122 proliferation with an IC 50 of 20 nM (Fig. 3D) . Taken together, our findings indicate that EML4-ALK is a sensitive HSP90 client.
HSP90 inhibition causes regression of EML4-ALK-driven H3122 xenografts and murine lung adenocarcinomas
To We next treated tumor-bearing EML4-ALK transgenic mice with 17-DMAG.
Similar to the results with H3122 xenografts, we observed an average of 84% tumor
Research. Table S4 ) within one week of treatment (Fig. 5A, mouse 292 ).
Histological analysis showed remnant cancer cells and dramatic restoration of normal lung structure (Fig. 5B) . We continued to treat these mice for an extended period of time, and documented tumor volume each week by MRI (Fig. 5A and Table S4 ). Our results showed that tumor response was not durable, and varied significantly among mice during treatment (Table S4 ).
To determine whether 17-DMAG impacted survival, we compared treatment with 17-DMAG to placebo. Median survival increased from 7 weeks in the placebo group to 21 weeks in the 17-DMAG-treated group, (p < 0.0001) (Fig. 5C ). This improvement in overall survival was noted even though the durability of response did not match that achieved with TAE684 (Fig. 6A ).
We also performed pharmacodynamic studies using tumors from the (Fig. 6C ).
Research. A recently published study described a mouse lung cancer model initiated by constitutively over-expressed EML4-ALK driven by lung-specific Surfactant C (SPC)
promoter. This transgenic model also showed responses to an ALK-specific inhibitor (43) . However, the short life span of these mice after birth, due to early expression of EML4-ALK in the late stage of embryonic development, potentially limits its use in performing comparative studies of different treatment strategies. We thus developed a new EML4-ALK mouse lung cancer model that phenocopies the molecular features of human ALK-rearranged lung cancer, and allows us to compare and prioritize therapeutic approaches.
Using this model, we demonstrate that inhibition of ALK activity, using TAE684, is more effective than conventional chemotherapy ( Figure 1C ). The degree of tumor regression is analogous to that of EGFR kinase inhibitors used to treat mutant
Research. In order to identify other potential therapeutic targets, we demonstrate the association of EML4-ALK with several intracellular chaperones, including HSP90
( Figure 3B ). Previous studies suggested that NPM-ALK is also a client of HSP90 and HSP70 (45) (46) (47) . We further demonstrated that geldanamycin compounds caused dissociation of HSP90 from EML4-ALK, and were effective in vitro, as well as in a xenograft model and in our murine adenocarcinoma model in vivo. In fact, 17-DMAG ranked second of the four treatments evaluated in the EML4-ALK-driven murine lung adenocarcinomas, and was more effective than chemotherapy and combined PI3K/mTOR/MEK inhibition ( Fig. 6A and 6D ). Despite impressive initial responses to 17-DMAG responses were not durable.
This result is similar to those observed with geldanamycins used to treat murine adenocarcinomas harboring EGFR mutation (19, 48) . The mechanism by which resistance develops is presently not defined. However we detected upregulation of HSP70 in mice that have developed resistance to 17-DMAG (Fig. 6C) 
